Agentix Australia

Agentix is a biotechnology company focused on developing novel therapeutics that modulate the endocannabinoid system to treat metabolic and inflammatory diseases. The company's lead programs utilize synthetic ligands targeting cannabinoid receptors, specifically designed to provide therapeutic benefits without the central nervous system side effects typically associated with cannabinoid therapies. Agentix Australia was established to leverage the Australian clinical trial ecosystem and R&D tax incentives for its early-stage pipeline. Their primary focus includes addressing global health challenges such as obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The company's lead candidate, AGTX-201, is a peripherally restricted CB1 receptor antagonist.